ID   PCI-04B
AC   CVCL_C171
SY   PCI-4B; PCI4B; PCI-4M; PCI-4.2
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 989
DR   cancercelllines; CVCL_C171
DR   Cell_Model_Passport; SIDM00043
DR   Cosmic-CLP; 1298531
DR   DepMap; ACH-002297
DR   EGA; EGAS00001000978
DR   GDSC; 1298531
DR   GEO; GSM827146
DR   GEO; GSM1670344
DR   PharmacoDB; PCI4B_1253_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_C171
DR   Wikidata; Q54938650
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RX   PubMed=2766286;
RX   PubMed=8084624;
RX   PubMed=14996750;
RX   PubMed=17312569;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.38%; Native American=0%; East Asian, North=1.29%; East Asian, South=0%; South Asian=0%; European, North=61.21%; European, South=37.12% (PubMed=30894373).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 10,11
ST   D16S539: 12,13
ST   D5S818: 12
ST   D7S820: 12,13
ST   TH01: 6,7
ST   TPOX: 9
ST   vWA: 16,18
DI   NCIt; C4044; Laryngeal squamous cell carcinoma
DI   ORDO; Orphanet_494550; Squamous cell carcinoma of the larynx
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C170 ! PCI-04A
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 27
//
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RA   Carey T.E.;
RT   "Head and neck tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York (1994).
//
RX   PubMed=2766286;
RA   Heo D.S., Snyderman C.H., Gollin S.M., Pan S., Walker E., Deka R.,
RA   Barnes E.L., Johnson J.T., Herberman R.B., Whiteside T.L.;
RT   "Biology, cytogenetics, and sensitivity to immunological effector
RT   cells of new head and neck squamous cell carcinoma lines.";
RL   Cancer Res. 49:5167-5175(1989).
//
RX   PubMed=8084624; DOI=10.1177/01945998941113P105;
RA   Snyderman C.H., Klapan I., Milanovich M., Heo D.S., Wagner R.,
RA   Schwartz D.R., Johnson J.T., Whiteside T.L.;
RT   "Comparison of in vivo and in vitro prostaglandin E2 production by
RT   squamous cell carcinoma of the head and neck.";
RL   Otolaryngol. Head Neck Surg. 111:189-196(1994).
//
RX   PubMed=14996750; DOI=10.1158/0008-5472.CAN-03-2968;
RA   Wang J., Xi L.-Q., Hunt J.L., Gooding W., Whiteside T.L., Chen Z.,
RA   Godfrey T.E., Ferris R.L.;
RT   "Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in
RT   squamous cell carcinoma of the head and neck identifies a novel
RT   metastatic phenotype.";
RL   Cancer Res. 64:1861-1866(2004).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//